Two Sigma Investments
LVTX

Two Sigma Investments’s LAVA Therapeutics LVTX Stock Holding History

Two Sigma Investments’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,412
Closed -$45.4K – 3810
2025
Q2 		$45.4K Sell
34,412
-23,303
-40% -$29.7K ﹤0.01% 3071
2025
Q1 		$73.3K Buy
57,715
+8,943
+18% +$9.95K ﹤0.01% 2998
2024
Q4 		$46.4K Sell
48,772
-53,994
-53% -$84.8K ﹤0.01% 3053
2024
Q3 		$171K Sell
102,766
-9,673
-9% -$17.7K ﹤0.01% 2825
2024
Q2 		$202K Buy
112,439
+30,408
+37% +$80.3K ﹤0.01% 2728
2024
Q1 		$273K Buy
+82,031
New +$181K ﹤0.01% 2597

Other funds holding LVTX

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Two Sigma Investments's LVTX Position: Q3 2025 in Review

Two Sigma Investments sold out of LAVA Therapeutics (LVTX) in Q3 2025, closing a stake of 34,412 shares — an estimated $45.4K sold.

Two Sigma Investments first reported a position in LVTX in Q1 2024 and held it in 6 quarters. The position peaked at $273K in Q1 2024. 21 funds tracked by Wall St. Rank hold LVTX as of Q3 2025.

  • Two Sigma Investments reported no remaining LAVA Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Investments sold 34,412 LAVA Therapeutics shares in Q3 2025, an estimated $45.4K.
  • Two Sigma Investments first reported a position in LAVA Therapeutics in Q1 2024 and held it in 6 quarters.
  • Two Sigma Investments's LAVA Therapeutics position peaked at $273K in Q1 2024.
  • 21 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2025.

Based on Two Sigma Investments's 13F filing for Q3 2025, filed 14 Nov 2025.